

Benefit Coverage

Covered Benefit for lines of business including:
Health Benefits Exchange (HBE), RItE Care (MED), Children with Special Needs (CSN), Substitute Care (SUB), Rhody Health Partners (RHP), Rhody Health Expansion (RHE), Medicare-Medicaid Plan (MMP) Integrity
Excluded from Coverage:
Extended Family Planning (EFP)

Description

A continuous glucose monitoring system (CGMS) is an FDA-approved device that records glucose levels throughout the day and night, using a sensor which is inserted under the skin. The system automatically records an average glucose value every 5 minutes for up to 72 hours, while the person with diabetes continues daily activities at home. The sensor measures the level of glucose in the tissue every 10 seconds and sends the information via a wire to a pager-sized device called a "monitor."

The most important use of continuous blood glucose monitoring is to facilitate adjustments in therapy to improve control.

Situations which support 3 day monitoring with a continuous glucose monitoring device include adjustments in therapy, quantifying the response in a trial of a diabetes therapy, assessing the impact of lifestyle modifications on glycemic control, and monitoring when attempting to tighten control without causing hypoglycemia.

Criteria

Requires Authorization	Prior authorization is required.
	When medical necessity criteria are met, Neighborhood members are allowed coverage for <ol style="list-style-type: none"> 1. Episodic Continuous Glucose Monitoring 2. Long Term (greater than 72 hours) Continuous Glucose Monitoring

Episodic Continuous Glucose Monitoring

Intermittent monitoring (72 hours) of glucose levels in interstitial fluid may be considered medically necessary and covered if the following criteria are met:

Note that 2 (72 hour) monitoring sessions are covered per 12 month period with Prior Authorization.

- ☐ Patients with type I diabetes who despite current use of best practices have poorly controlled diabetes, including hemoglobin A1c not in acceptable target range for the patient's clinical situation, unexplained hypoglycemic episodes, hypoglycemic unawareness, suspected postprandial hyperglycemia, or recurrent diabetic ketoacidosis.
- ☐ Patients with type I diabetes prior to insulin pump initiation to determine basal insulin levels.
- ☐ Women with type I diabetes who are pregnant or about to become pregnant and have poorly controlled diabetes.

▶ **NOTE:** In the event the ordering practitioner prescribes a third monitoring episode in the twelve month period, submission of current documentation of all of the above criteria will be required in order to consider the request for authorization.

Long Term (greater than 72 hours) Continuous Glucose Monitoring

This may be considered medically necessary as an adjunct to finger stick testing of blood glucose when the following criteria are met:

- ☐ Type 1 diabetes (as evidenced by submitted C peptide laboratory result) AND
- ☐ Recurrent episodes of severe hypoglycemia (defined as hypoglycemia [blood glucose less than 50 mg/dL]) and clinical documentation of wide fluctuations of blood glucose levels despite appropriate modifications in insulin regimen and compliance with frequent self-monitoring or pregnancy.

Authorization Forms

Please access Prior Authorization forms by visiting Neighborhood's website at www.nhpri.org.

1. Go to the section for Providers
2. Click on "Resources & FAQ's"
3. Click on "Medical Management Request Forms"- forms are listed alphabetically by program.

[Prior Authorization Forms](#)

For assistance with prior authorizations please contact Clinical Administrative Support at 401-459-6060.

Fax authorization forms to 401-459-6023.

Covered Codes: For information on Coding please reference the [Authorization Quick Reference Guide](#)

Exclusions

Home Blood Glucose disposable monitors, including test strips A9275 is non-covered because these monitors do not meet the definition of DME. DME is equipment which:

- Can withstand repeated use; i.e., could normally be rented and used by successive patients;
- Is primarily and customarily used to serve a medical purpose;
- Generally is not useful to a person in the absence of illness or injury; and,
- Is appropriate for use in a patient's home

- Gluco Watch G2
- Remote Glucose Monitoring
- Glucose monitoring in non-diabetic persons following gastric bypass surgery
- Glucose monitoring for nesidioblastosis (primary islet cell hypertrophy)

CMP Cross Reference:

Created:	09/2007
Annual Review Month:	March
Review Dates:	3/02/11, 3/10/12, 2/26/13, 3/18/2014, 3/3/2015, 12/15/2016, 1/9/18
Revision Dates:	7/03/09, 2/22/10, 3/12/13, 3/3/2015, 07/1/2016, 12/15/2016
CMC Review Date:	3/09/10, 3/08/11, 3/10/12, 3/12/13, 03/18/14, 3/3/2015, 1/10/2017, 1/9/18
Medical Director	1/15/08, 7/14/09, 3/9/2010, 3/15/11, 4/5/12, 4/1/13, 3/21/2014,
Approval Dates:	3/3/2015, 2/16/2017, 4/12/18
Effective Dates:	3/21/2014, 3/3/2015, 7/1/2016, 2/16/2017, 4/12/18

Neighborhood reviews clinical medical policies on an annual base.

Disclaimer:

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's coverage plan; a member's coverage plan will supersede the provisions of this medical policy. For information on member-specific benefits, call member services. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. Neighborhood reserves the right to review and revise this policy for any reason and at any time, with or without notice.

References:

Buckingham, Bruce, for the Diabetes Research in Children Network (DirecNet) Study Group, “Continuous Glucose Monitoring in Children with Type 1 Diabetes”, Journal of Pediatrics, vol 151, no 4 (October, 2007).

Eisenbarth, George, “Update in Type 1 Diabetes”, Journal of Clinical Endocrinology and Metabolism, vol 92, no. 7, p 2403-2407.

Garg, Satish and Lois Jovanovic, “Relationship of Fasting and Hourly Blood Glucose Levels to HbA1c Values”, Diabetes Care, vol 29, no. 12, (Dec., 2006), p 2644-2649. (STS-7)

Garg, Satish, et al, “The Role of Continuous Glucose Sensors in Diabetes Care”, Endocrinology and Metabolism Clinics, vol 33, no. 1 (March 2004).

<http://www.fda.gov/cdrh/pdf5/p050012s001.html>. (safety and effectiveness, STS-7)

Bloomgarden, D, Freeman, J et al. Early Patient and Clinician Experiences with Continuous Glucose Monitoring; <http://spectrum.diabetesjournals.org/content/21/2/128.full>

Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes; New England Journal of Medicine. 2008; Volume 359 (14):1464-1476

De Block C, Vertommen J et al, Minimally –invasive and non-invasive continuous glucose monitoring systems: indications, advantages, limitations and clinical aspects. Current Diabetes rev. 2008 Aug; 4(3):159-68

Battelino T, Bolinder J, Clinical use of real-time continuous glucose monitoring. Current Diabetes Review. 2008 Aug; 4(3):218-22

Golicki DT, Golicka D et al. Continuous Glucose Monitoring System in children with type 1 diabetes mellitus: a systematic review and meta-analysis. Diabetologia. 2008 Feb; 51(2):233-40.

Klonoff D. Continuous Glucose Monitoring: Roadmap for 21st century diabetes therapy. Diabetes Care, Vol 28 (5) May 2005.

Ellis SL, Naik RG et al. Use of continuous glucose monitoring in patients with type 1 diabetes; Current Diabetes Review. 2008 Aug; 4(3) 207-17

Charlton M. Commentary: The technology of continuous glucose monitoring. British Medical Journal 2008; 337:a1733